AN

Ananda Pharma Plc

Develops approved cannabinoid medicines for pain, epilepsy, and heart failure.

ANAN | Aquis Stock Exchange

Overview

Corporate Details

ISIN(s):
GB00BDQPXQ60
LEI:
894500DFM8VOC5FW4X47
Country:
United Kingdom
Address:
6th Floor, 60 Gracechurch Street, EC3V 0HR London
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ananda Pharma Plc is a biopharmaceutical company focused on developing and commercializing regulatory-approved medicines derived from cannabinoids. The company targets complex conditions with significant unmet medical needs, primarily focusing on chronic inflammatory pain (including chemotherapy-induced peripheral neuropathy and endometriosis), drug-resistant epilepsies, and heart failure with preserved ejection fraction (HFpEF). Its integrated approach spans research, drug candidate development, clinical trials conducted with research partners, and navigating regulatory pathways for marketing authorization. Ananda Pharma leverages the well-understood safety profile of cannabinoids to potentially accelerate its clinical development programs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 08:20
Regulatory News Service
Confirmation of receipt of £168k R&D tax refund
English 23.0 KB
2025-10-13 15:45
Interim Report
Interims for the six months ended 31 July 2025
English 129.3 KB
2025-09-26 12:10
Legal Proceedings Report
Ananda ends UCL/GOSH trials, prioritises MRX1
English 22.6 KB
2025-09-16 08:00
Regulatory News Service
Ananda attending Cannabinoid Summit
English 22.1 KB
2025-08-26 15:43
Post-Annual General Meeting Information
Result of Annual General Meeting
English 29.6 KB
2025-08-19 08:00
Report Publication Announcement
Webinar Presentation Release
English 21.3 KB
2025-07-30 14:49
Pre-Annual General Meeting Information
Notice of Annual General Meeting
English 21.8 KB
2025-07-30 13:44
Report Publication Announcement
Publication of Annual Report
English 44.2 KB
2025-06-23 08:00
Regulatory News Service
Key Milestone in MRX1 Path to Clinical Trials
English 23.3 KB

Automate Your Workflow. Get a real-time feed of all Ananda Pharma Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ananda Pharma Plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ananda Pharma Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Kairos Pharma, LTD. Logo
Develops novel oncology therapies to reverse drug resistance and immune suppression.
United States of America
KAPA
KAKEN PHARMACEUTIAL CO., LTD. Logo
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan
4521
KALA BIO, Inc. Logo
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America
KALA
Kalaris Therapeutics, Inc. Logo
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America
KLRS
KalVista Pharmaceuticals, Inc. Logo
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America
KALV
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel
KMDA
KAMADA LTD Logo
Develops specialty plasma-derived therapeutics for rare and serious diseases.
United States of America
KMDA
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom
KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden
KAN
KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea
217730

Talk to a Data Expert

Have a question? We'll get back to you promptly.